P450 mutant enzyme as well as preparation method and application thereof
By expressing the P450 mutant enzyme in E. coli for enzymatic reaction, the problems of complicated and poor safety of synthesis steps of p-hydroxyacetophenone and p-hydroxybenzone in the prior art are solved, and efficient and low-cost production is achieved. It has significant industrial application potential.
Patent Information
- Application Number
- CN202411424100.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing synthesis methods of para-hydroxyacetophenone and para-hydroxybenzone have problems such as cumbersome steps, poor operational safety, many by-products, scarce catalysts and low product yields, and require a green, safe and efficient production method.
Using P450 mutant enzyme, the gene recombinant vector containing specific amino acid sequences is expressed in E. coli, and the enzymatic reaction is carried out to synthesize p-hydroxyacetophenone and p-hydroxybenzone, using acetophenone or p-hydroxybenzone, coenzyme Enzymatic reaction with P450 mutant enzyme under specific conditions.
It has achieved high catalytic activity, strong regional selectivity, low enzyme dosage, low cost, short reaction time and high product purity, significantly reducing production costs and having industrial application potential.
Smart Images

Figure CN119040285A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioengineering, in particular to a P450 mutant enzyme and a preparation method and application thereof. Background Art
[0002] P450 enzymes, the full name of which is cytochrome P450 enzymes, are a class of heme proteins that are widely present in organisms and are involved in the metabolism of a variety of endogenous and exogenous compounds. The typical reaction catalyzed by P450 enzymes is a monooxygenase reaction, in which the substrate is oxidized and molecular oxygen is reduced to water. During the reaction, electrons are usually transferred to heme by the reduced coenzyme NADPH through the electron transport chain. P450 enzymes have always been an important tool in scientific research and drug development due to their important role in organisms and their potential in biotechnology applications.
[0003] Para-hydroxyacetophenone is a bile-stimulating drug, commonly used as an auxiliary drug for the treatment of cholecystitis and acute and chronic icteric hepatitis. In addition, para-hydroxyacetophenone is also a raw material for fine chemical synthesis, mostly used in the synthesis of spices. Para-hydroxybutyrophenone can also be used as some important drug intermediates and starting materials for the synthesis of more complex organic molecules.
[0004] At present, the main methods for synthesizing p-hydroxyacetophenone and p-hydroxybutyrophenone include Fries rearrangement method, Friedel-Crafts acylation method and diazotization method. These synthesis methods require the use of a large amount of acid, alkali and highly toxic substances or catalysts that are difficult to obtain, and there are problems such as corrosion of equipment, pollution of the environment, difficulty in post-treatment, low yield, and cumbersome steps. The biosynthesis method has the advantages of being green, environmentally friendly, environmentally friendly, simple to operate, and highly selective;
[0005] In summary, the existing production methods of p-hydroxyacetophenone and p-hydroxybutyrophenone have the problems of complicated steps, poor operation safety, many by-products, scarce catalysts, low product yield, etc. Therefore, it is necessary to find a green and safe method to increase the yield of p-hydroxyacetophenone and p-hydroxybutyrophenone while reducing the production cost. For this purpose, an application of a P450 mutant enzyme in the synthesis of p-hydroxyacetophenone and p-hydroxybutyrophenone is provided. Summary of the invention
[0006] The purpose of the present invention is to provide a P450 mutant enzyme and a preparation method and application thereof to solve the problems raised by the above-mentioned background technology in view of the defects of the prior art.
[0007] To achieve the above object, the present invention provides the following technical solution: a P450 mutant enzyme, wherein the amino acid sequence of the enzyme is selected from SEQ ID NO.1 and the alanine at position 82 is mutated to phenylalanine.
[0008] A method for preparing a P450 mutant enzyme comprises the following steps: constructing a gene recombinant vector containing a sequence of SEQ ID NO.1, transferring the vector into Escherichia coli after point mutation, and culturing the vector to obtain a recombinant Escherichia coli bacterial liquid; and lysing the recombinant Escherichia coli bacterial liquid to obtain a P450 mutant enzyme liquid.
[0009] Application of a P450 mutant enzyme in the synthesis of p-hydroxyacetophenone and p-hydroxybutyrophenone.
[0010] As a further preferred embodiment of the present invention, the specific application method is: acetophenone or butyrophenone, coenzyme, P450 mutant enzyme, and phosphate buffer are mixed to carry out enzymatic reaction, and p-hydroxyacetophenone or p-hydroxybutyrophenone is obtained after the reaction is completed.
[0011] As a further preferred embodiment of the present invention, the molar ratio of the P450 mutant enzyme to acetophenone or butyrophenone is 1:1-200.
[0012] As a further preferred embodiment of the present invention, the temperature of the enzymatic reaction is 25-35° C., the pH value of the enzymatic reaction is 7.0-9.0, and the enzymatic reaction time is 2-8 h.
[0013] As a further preferred embodiment of the present invention, the coenzyme concentration is 0.1-2 mM.
[0014] As a further preferred embodiment of the present invention, the coenzyme is NADPH.
[0015] Compared with the prior art, the present invention has the following beneficial effects: compared with the chemical synthesis method, the P450 mutant in the present invention has good catalytic activity and good regioselectivity of para-hydroxylation, has the significant advantages of small enzyme dosage, low enzyme preparation cost, short reaction time, high product yield and purity, can greatly reduce the production cost of p-hydroxyacetophenone and p-hydroxybutyrophenone, and has strong industrial application potential. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 It is a structural schematic diagram of the present invention;
[0017] Figure 2 This is the gel image before and after the induction of the P450 protein of the present invention;
[0018] Figure 3 HPLC chart of acetophenone and p-hydroxyacetophenone in Example 4 of the present invention;
[0019] Figure 4 HPLC chart of butylphenone and p-hydroxybutylphenone in Example 5 of the present invention. DETAILED DESCRIPTION
[0020] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making a clearer and more definite definition of the protection scope of the present invention.
[0021] Example 1: Construction of cytochrome P450 monooxygenase vector;
[0022] The gene sequence of the R-aminotransferase of the present invention is derived from the Uniprot database sequence number: P14779, which is transferred to the pET15b vector. The plasmid map is as follows: Figure 1 shown.
[0023] Example 2: Site-directed mutagenesis of cytochrome P450 monooxygenase;
[0024] The wild-type cytochrome P450 monooxygenase gene was subjected to site-directed mutagenesis using megaprimer PCR mutagenesis technology. Taking the 82nd amino acid mutation as an example, a pair of primers were first designed for the mutation site.
[0025] The primers used were:
[0026] Upstream primer: 5'-CGCGATTTTTTTGGCGATGGCCTGTTTACCAGT-3',
[0027] Downstream primer: 5′-ATCGCCAAAAAAATCGCGAACAAATTTCAG-3′.
[0028] The PCR system (25 μL) is as follows: 1 ng template, 0.5 μL of each pair of mutant primers (10 μM), 0.5 μL Phanta polymerase, 12.5 μL 2*buffer, 0.5 μL 10 mm dNTP, and sterile distilled water to 25 μL.
[0029] The PCR reaction procedure was as follows: (1) denaturation at 98°C for 3 min; (2) denaturation at 98°C for 30 sec; (3) annealing at 55°C for 30 sec; (4) extension at 72°C for 5 min. Steps (2) to (4) were repeated for 30 cycles, followed by extension at 72°C for 5 min and storage of the product at 12°C. The amplified PCR product was detected by 1% agarose gel electrophoresis, and a band with the same length as the P450-BM3 gene was observed. It was judged that the gene encoding the target mutant had been amplified, so the restriction endonuclease DpnI was directly added to the PCR product, and 10 μL was transferred to E. coli DH5ɑ competent cells after digestion at 37°C for 15 minutes, and then heat-shocked in a 42°C water bath for 60-90 seconds; after being placed on ice for 5 minutes, 500 μL LB culture medium was added, and then activated at 37°C shaker at 200 rpm for 1 hour, and evenly coated on LB solid culture dishes containing 75 μg / mL ampicillin resistance. After overnight culture at 37°C, single clones were selected and cultured in 10 mL LB liquid culture medium containing 75 μg / mL ampicillin resistance, and then sent to General Bio (Anhui) Co., Ltd. for sequencing. The sequencing results were compared with the P450 monooxygenase sequence using Geneious software, and the 82nd position mutated to phenylalanine. The resulting mutant was named P450A82F.
[0030] Example 3: Expression and purification of P450 mutant proteins;
[0031] In the above steps, the obtained recombinant plasmid is first accurately transferred into the Escherichia coli expression strain BL21 (DE3), and then it is spread on a solid culture medium with ampicillin resistance and inverted in an incubator for overnight culture at 37°C. Then pick the plaques and inoculate them in the liquid LB culture medium, and culture them overnight at 37°C. Next, the obtained strain is inoculated into the culture medium containing ampicillin resistance at a ratio of 1:100 at 37°C and 220r / min for expansion culture. When the optical density (OD600) of the bacterial solution reaches 0.6-0.8, IPTG with a final concentration of 0.2mmol / L is added to induce protein expression, and the expression is continued at 25°C for 14-16 hours. After the culture is completed, the bacteria are collected by centrifugation. The P450 enzyme protein can be obtained by high-pressure crushing and Ni affinity chromatography of the bacteria. The specific method is as follows: the nickel column used for purification (column volume 1mL). Pre-balance with buffer A (50mM potassium phosphate buffer, 150mM NaCl, pH 8.0), load the sample after balancing, elute the unbound protein in the affinity column with 20 column volumes (20mL) of binding solution, and then use 10 column volumes (10mL) of buffer B (50mM potassium phosphate buffer, 150mM NaCl, 250mM imidazole, pH 8.0) for gradient elution. Collect the eluate containing the target protein and dialyze overnight to remove the imidazole therein. Then use an ultrafiltration tube with a molecular weight cutoff of 50kDa to concentrate the protein to about 2mL by centrifugation, and store it in a -80℃ environment for a long time after aliquoting for standby use.
[0032] In order to verify the accuracy of the protein, SDS-PAGE electrophoresis can be used to detect its molecular weight. Figure 2 The results shown in (gel image) show that the molecular weight of the transaminase is about 130 kDa, which is close to the theoretical molecular weight of 120 kDa, indicating that the recombinant P450 mutant protein was successfully obtained.
[0033] Example 4: P450 mutant enzyme reaction to produce p-hydroxyacetophenone;
[0034] Reaction system with acetophenone as substrate: the reaction solution contains 10 mM acetophenone, 1 mM NADPH, 100 mM phosphate buffer (pH=8), 5 μmol P450A82F enzyme, and 5% DMSO, and reacts at 30° C. in the dark for 30 min, at 220 rpm.
[0035] The reaction was performed at 0h, 1h, 2h, 4h, 6h, 12h, and 24h. After the reaction was completed, the reaction was terminated on ice. The peak value was found by detection when it reached 6h. The sample was centrifuged at 13000rpm / min for 30min, and then filtered with a 0.45um filter head; stored at 4℃ for detection; the reaction detection results were as follows Figure 3 .
[0036] The reaction equation of the catalytic reaction is:
[0037]
[0038] Detection method:
[0039] The model of the high performance liquid chromatograph in the laboratory is Japan Shimadzu LC-20, and the chromatographic column selected is ZORBAX SB-C18 reverse phase chromatographic column.
[0040] Mobile phase A: pure water containing 0.1% formic acid;
[0041] Mobile phase B: pure acetonitrile; the ratio of mobile phase A liquid and mobile phase B liquid was 40:60, the flow rate was 1 mL / min, the detection wavelength was 254 nm, and the column temperature was 30°C.
[0042] Example 5: P450 enzyme reaction to produce p-hydroxybutyrophenone;
[0043] Reaction system with phenylbutyric acid as substrate: the reaction solution contains 10mM phenylbutyric acid, 1mM NADPH, 100mM phosphate buffer (pH=8), 5μmol P450 enzyme, and 5% DMSO at 30℃ and 220rpm in the dark; react for 6h. After the reaction is completed, put it on ice to terminate the reaction; centrifuge the sample at 13000rpm / min for 30min, and then filter it with a 0.45um filter head; store it at 4℃ for detection; the reaction detection results are as follows Figure 4 ;
[0044] The reaction equation of the catalytic reaction is:
[0045]
[0046] Detection method:
[0047] The model of the high performance liquid chromatograph in the laboratory is Shimadzu LC-20, and the selected chromatographic column is ZORBAX SB-C18 reverse phase column. Mobile phase A: water containing 0.1% formic acid. Mobile phase B: pure acetonitrile, the ratio of mobile phase A liquid to B liquid is 40:60, the flow rate is 1mL / min, the detection wavelength is 254nm, and the column temperature is 30℃.
[0048] Example 6: P450 mutant whole cell catalytic reaction;
[0049] After the P450 mutant cells were induced to ferment, the bacterial liquid was collected by centrifugation at 4°C and 500rpm, and then washed twice with 100mM phosphate buffer, and then resuspended with 100mM phosphate buffer to OD600=20 to obtain a cell suspension, which was placed in a -20°C refrigerator for use. Cell catalytic reaction system: 5mL of cell suspension, 0.5g glucose, 10mM acetophenone / butyrophenone solution, 100mM phosphate buffer (PH=8.0), and pure water was added to 10mL. The reaction system was mixed in a 100mL conical flask. Protect from light, 30°C, 200rpm for 6h.
[0050] Detection method:
[0051] After the reaction, the reaction solution was extracted with an equal volume of ethyl acetate for three times, then dried, dissolved with an equal volume of acetonitrile, and sampled for detection; the chromatographic column was a Zorbax Eclipse XDB-C18 column, and the product amount was detected: the mobile phase was: mobile phase A: water containing 0.1% formic acid. Mobile phase B: pure acetonitrile, the ratio of mobile phase A liquid and B liquid was 40:60, the flow rate was 1 mL / min, the detection wavelength was 254 nm, and the column temperature was 30°C.
[0052] The above embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.
Claims
1. A P450 mutant enzyme, characterized in that The amino acid sequence of the enzyme is selected from SEQ ID NO. 1 and the alanine at position 82 is mutated to phenylalanine.
2. A method for preparing a P450 mutant enzyme as claimed in claim 1, characterized in that: The specific preparation includes the following steps: constructing a gene recombinant vector containing the sequence SEQ ID NO.1, and transferring it into Escherichia coli after point mutation, culturing to obtain recombinant Escherichia coli bacterial liquid; lysing the recombinant Escherichia coli bacterial liquid to obtain P450 mutant enzyme liquid.
3. Use of the P450 mutant enzyme as claimed in claim 1 in the synthesis of p-hydroxyacetophenone and p-hydroxybutyrophenone.
4. The use according to claim 3, characterized in that: The specific application method is: acetophenone or butyrophenone, coenzyme, P450 mutant enzyme and phosphate buffer are mixed to carry out enzymatic reaction, and p-hydroxyacetophenone or p-hydroxybutyrophenone is obtained after the reaction is completed.
5. The use according to claim 4, characterized in that: The molar ratio of the P450 mutant enzyme to acetophenone or butyrophenone is 1:1-200.
6. The use according to claim 4, characterized in that: The temperature of the enzymatic reaction is 25-35° C., the pH value of the enzymatic reaction is 7.0-9.0, and the enzymatic reaction time is 2-8 hours.
7. The use according to claim 4, characterized in that: The coenzyme concentration is 0.1-2 mM.
8. The use according to claim 4, characterized in that: The coenzyme is NADPH.
